4Balow J E, Austin H A 3rd, Muenz L R, et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis [J]. N Engl J Med, 1984, 311 (8) :491-495.
5Austin H A 3rd, Klippel J H, Balow J E, et al .Therapy of lupus nephritis. Controlled trial of prednisone and eytotoxie drugs [J]. N Engl J Med, 1986, 314 (10) : 614-619.
6Mills J A. Systemic lupus erythematosus [J]. N Engl J Med, 1994, 330 (26) : 1871-1879.
7Gourley M F, Austin H A 3rd, Scott D, et al. Methylprednisolone and cyelophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial [J]. Ann Intern Med, 1996, 125 (7) : 549-557.
8Mok C C, Ying K Y, Tang S,et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis [J]. Arthritis Rheum, 2004,50 (8) : 2559-2568.
9Houssiau F A, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyelophosphamideIJ]. Arthritis Rheum, 2002, 46 (8) : 2121-2131.
10Boumpas D T, Austin H A 3rd, Vaughan E M, et al. Risk for heart pathological changes in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy [J]. Ann Intern Med, 1993, 119(5): 366-369.
